Mucommune is a privately-held startup focused on women's reproductive health. The lead product focuses on enabling non-hormonal contraception, in the form of anti-sperm antibodies that can be dosed from an intravaginal ring for month long contraception, or via instantly-dissolving tablets for on-demand contraception. Clinical data with a first-generation antibody demonstrated exceptional potency with this approach; our second generation molecule is expected to further enhance efficacy while lowering dose and costs. The second product is a non-antibiotics treatment and prophylaxis for bacterial vaginosis, the most prevalent STI in the world. Mucommune is led by an experienced team with over 5 decades of R&D experience in women's health advancing products from concept through registration-quality Phase 3 trials, with multiple FDA-approved products, and is funded by over $12M in non-dilutive funding. We anticipate filing INDs for both products in 2024.
Privately Funded Company
Company HQ State:
Company HQ Country:
2016 Inhalon Biopharma, a clinical stage company, was spun out of Mucommune in 2019.
Main Therapeutic Focus:
Lead Product in Development:
MM-008: anti-sperm antibody for non-hormonal contraception.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):